These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Drug product equivalence--the problem, the challenge, and the U.S.P. Macek TJ Am J Pharm Sci Support Public Health; 1971; 143(6):188-94. PubMed ID: 5140167 [No Abstract] [Full Text] [Related]
4. How good are our drugs? Miller LC Am J Hosp Pharm; 1970 May; 27(5):367-74. PubMed ID: 5422276 [No Abstract] [Full Text] [Related]
5. USP standards for dissolution and bioavailability. Grady LT Am J Hosp Pharm; 1982 Sep; 39(9):1546-8. PubMed ID: 7137198 [No Abstract] [Full Text] [Related]
6. Editorial: Standardization of drug names. Lewis JR JAMA; 1974 Jul; 229(5):559-60. PubMed ID: 4406902 [No Abstract] [Full Text] [Related]
7. USP and the development of drug standards. Banes D J Chem Inf Comput Sci; 1977 May; 17(2):95-6. PubMed ID: 853070 [No Abstract] [Full Text] [Related]
8. Public standards for drugs: reflections on their use by the professions and industry. Miller LC Hosp Formul; 1976 Mar; 11(3):151-5. PubMed ID: 1026682 [No Abstract] [Full Text] [Related]
9. Relationship of USP-NF to NDA and ANDA "Standards". Belson JJ Am J Hosp Pharm; 1982 May; 39(5):869-70. PubMed ID: 7081269 [No Abstract] [Full Text] [Related]
10. Equivalence studies for complex active ingredients and dosage forms. Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632 [TBL] [Abstract][Full Text] [Related]
11. The value of USP public standards for therapeutic products. Bhattacharyya L; Cecil T; Dabbah R; Roll D; Schuber S; Sheinin EB; Williams RL; Pharm Res; 2004 Oct; 21(10):1725-31. PubMed ID: 15553215 [No Abstract] [Full Text] [Related]
13. Voluntary standards--the USP and the PDA. Schmitz AJ J Parenter Drug Assoc; 1980; 34(6):425-6. PubMed ID: 6906364 [No Abstract] [Full Text] [Related]
14. New York State and drug lists: a history of confusion. Stetler CJ Med Mark Media; 1978 Sep; 13(9):36, 38, 40 passim. PubMed ID: 10316687 [No Abstract] [Full Text] [Related]
15. Information that brand-name companies do not tell us. Marcoux AW Drug Intell Clin Pharm; 1987 Mar; 21(3):296-7. PubMed ID: 3569035 [No Abstract] [Full Text] [Related]
16. USP to cut back on salt in drug names. Thompson CA Am J Health Syst Pharm; 2013 Jan; 70(2):94. PubMed ID: 23292260 [No Abstract] [Full Text] [Related]
18. The United States Pharmacopeia. Its value to the professions. Heller WM JAMA; 1970 Jul; 213(4):576-9. PubMed ID: 4914287 [No Abstract] [Full Text] [Related]
19. New term will distinguish tablets known to split in half. Thompson CA Am J Health Syst Pharm; 2012 Oct; 69(19):1619-21. PubMed ID: 22997111 [No Abstract] [Full Text] [Related]
20. Report on the PQRI impurity characterization and quantification best practices survey. Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396 [No Abstract] [Full Text] [Related] [Next] [New Search]